Difference between revisions of "Allergy & Intolerance"
StephenChu (talk | contribs) |
StephenChu (talk | contribs) |
||
| Line 60: | Line 60: | ||
*[[Media:Canadian_Approach_Allergy-Intolerance-AR-20110719c-post_meetg.pdf|Canadian model on Allergy & Intolerance (2011-07-19)]] Powerpoint in PDF format. | *[[Media:Canadian_Approach_Allergy-Intolerance-AR-20110719c-post_meetg.pdf|Canadian model on Allergy & Intolerance (2011-07-19)]] Powerpoint in PDF format. | ||
| + | |||
| + | *[[Media:AllergyIntolerance-LectureSlides_RussLeftwich.pdf|Allergy/Intolerance Topic Slides from Russ Leftwich, MD (2011-12-20)]] Powerpoint in PDF format. | ||
==Use Cases and Storyboards== | ==Use Cases and Storyboards== | ||
Revision as of 01:37, 21 December 2011
return to: Patient Care
Current work: Finish the work from the ballot resolution on the Allergy/Intolerance topic and have it published as DSTU.
Project 174
This is a work in progress. See HL7 Ballot site for existing specification.
This topic covers all interactions related to clinically recorded adverse reactions, including:
- Recording adverse reactions
- Revising existing adverse reaction records
- Retrieving a patient's adverse reaction records
These transactions are not intended for reporting adverse reactions (as managed by Individual Case Safety Reports). Rather, these transactions are intended to be recorded as part of a patient's electronic health record. They supplement allergy and intolerance records for circumstances where it is not clear whether an allergy or intolerance exists. These interactions are crafted to support a 'request-based' architecture in which messages are sent from a point of service (POS) such as a clinic, pharmacy, etc. to a central drug information system (DIS). These messages are phrased as requests because the DIS reserves the right to refuse all requests. Reasons might include the presence of contraindications such as drug-drug interactions or duplicate therapy, as well as more mundane issues such as lack of permission, lack of recorded patient consent, etc.
Contents
Patient Care WGM Agenda
Allergy/Intolerance Topic DSTU
The current "Allergy/Intolerance" topic DSTU expires in June 2012. The "Allergy/Intolerance" project group after some discussion recommends that application to HL7 publishing committee for a 12-month extension of the current DSTU should be considered as the best option forward. The 12-month extension will allow the group with time to perform proper DAM development and to determine how best the current DSTU may be modified and/or extended to meet updated, new requirements.
The following is DSTU extension guidance provided by HL7 HQ:
DSTU extension guidance is offered at the TSC wiki page under TSC Process Guidance, at: http://hl7t3f.org/wiki/index.php?title=DSTU_Publishing_Guidance, where requesting extensions to DSTU should use criteria determined in the TSC’s conference call 2009-03-09:
“Sufficient justification should be provided to describe effort in progress to move the standard towards a normative ballot, such as evidence of current trial activity, if they have a credible expectation that a normative document will be produced within a requested timeframe, given that trials are currently underway. The request must include the length of time required to extend the DSTU, including conclusion of the pilot and subsequent balloting activity...If you send the completed form to me (LynnL) I can put it on the TSC agenda.”
Allergy/Intolerance Topic: Project Scope Statement
Meeting Minutes
Presentations
- Canadian model on Allergy & Intolerance (2011-07-19) Powerpoint in PDF format.
- Allergy/Intolerance Topic Slides from Russ Leftwich, MD (2011-12-20) Powerpoint in PDF format.
Use Cases and Storyboards
Models
- Patient Care RMIM as of Jan 2007
- Patient Care RMIM as of May 2, 2007
- Updated Model as of May 22, 2007
